UNITED
STATES


SECURITIES
AND EXCHANGE COMMISSION


Washington,
D.C. 20549





FORM
10-Q




(Mark
One)


x QUARTERLY REPORT
UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934





For the
quarterly period ended June 30, 2009





o TRANSITION REPORT
UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT




Commission
file number: 000-31469





Medical
International Technology, Inc.


(Exact
name of small business issuer as specified in its charter)




Colorado
                    
                    84-1509950(State
      or other jurisdiction
                      of
      incorporation or organization)
                    
                    (IRS
      Employer Identification
No.)




1872
Beaulac


Ville
Saint-Laurent


Montrйal,
Quйbec, Canada H4R 2E7


(Address
of principal executive offices)





(514)
339-9355


(Issuer's
telephone number)





(Former
name, former address and former fiscal year, if changed since last
report)







Check
whether the issuer (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or
for such shorter period that the issuer was required to file such reports), and
(2)has been subject to such filing requirements for the past 90
days.    Yes  x    No   ̈




Indicate
by check mark whether the registrant has submitted electronically and posted on
its corporate Web site, if any, every Interactive Data File required to be
submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.495 of this
chapter) during the preceding 12 months (or for such shorter period that the
registrant was required to submit and post such
files).    Yes   ̈    No   ̈




Indicate by check mark whether the
registrant is a large accelerated filer, an accelerated filer, a non-accelerated
filer or a smaller reporting company filer. See definition of “accelerated
filer” and “large accelerated filer” in Rule 12b-2 of the Exchange Act (Check
one):




Large
      Accelerated Filer  ̈
              
              Accelerated
      Filer  ̈
              
              Non-Accelerated
      Filer  ̈
              
              Smaller Reporting Company x




Indicate
by check mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act). Yes o No x





The
number of shares outstanding of each of the issuer's classes of common equity as
of June 30, 2009: 57,344,375 shares of common stock















PART
      I.    FINANCIAL INFORMATIONItem
      1.      Consolidated Financial
      Statements
            3Consolidated
      Balance Sheet
            3Consolidated
      Statements of Operations,
            5Consolidated
      Statements of Cash Flows
            6Consolidated
      Statements of Comprehensive Loss
            7Notes
      to Unaudited Consolidated Financial Statements
            9Item
      2.       Management's Discussion and
      Analysis of Financial Condition and Plan of
    Operations
            13Item
      3.       Quantitative and Qualitative
      Disclosures About Market Risk
            14Item
      4.       Controls and
      Procedures
            15Part
      II. OTHER INFORMATIONItem
      1        Legal
      Proceedings
            15Item
      1A.    Risk Factors
            15Item
      2.       Unregistered Sales of Equity
      Securities and Use of Proceeds
            15Item
      3.       Defaults upon Senior
      Securities
            15Item
      4.       Submission of Matters to a
      Vote of Security Holders
            15Item
      5.       Other
    Information
            15Item
      6.       Exhibits and Reports on Form
      8-K
            15SIGNATURES
            16






2




Item
1. Financial Information




Medical
      International Technology, Inc.
            Quarterly Financial
      Report






CONSOLIDATED BALANCE SHEETJune
      30, 2009
                    
                    
                    September
      30, 2008(Unaudited)
                    
                    
                    (Audited)AssetsCurrent
      AssetsCash and cash
      equivalents
                    
                    $
                    100,109
                    
                    
                    $
                    94,834Accounts
      receivable
                    
                    
                    31,251
                    
                    
                    
                    ---Inventories
                    
                    
                    191,618
                    
                    
                    
                    169,459Prepaid
      expenses
                    
                    
                    3,557
                    
                    
                    
                    3,565Total
      Current Assets
                    
                    
                    326,535
                    
                    
                    
                    267,858Investment49% Participation
      in a joint venture company under the name of
                      "
      Jiangsu Hualan MIT Medical
      Technology (MIT China) Ltd"
                    
                    
                    406,100
                    
                    
                    
                    ---Property
      and EquipmentTooling and
      machinery
                    
                    
                    229,823
                    
                    
                    
                    229,823Furniture and
      office equipment
                    
                    
                    133,014
                    
                    
                    
                    133,014Leasehold
      improvements
                    
                    
                    22,163
                    
                    
                    
                    22,163385,000
                    
                    
                    
                    385,000Less
      accumulated depreciation
                    
                    
                    (337,558
                    )
                    
                    
                    (299,500
                    )47,442
                    
                    
                    
                    85,500Other
      AssetsPatents (net
      accumulated amortization of $1,747 and $1,398)
                    
                    
                    283
                    
                    
                    
                    632Total
      Assets
                    
                    $
                    780,360
                    
                    
                    $
                    353,990






3








Medical
      International Technology, Inc.
            Quarterly Financial
      Report






CONSOLIDATED BALANCE SHEETJune
      30, 2009
                          
                          
                          September
      30, 2008(Unaudited)
                          
                          
                          (Audited)Liabilities
      and Stockholders' Equity (Deficit)Current
      LiabilitiesDeferred
      income
                          
                          $
                          1,235,000
                          
                          
                          $
                          1,353,782Accounts payable
      and accrued expenses
                          
                          
                          295,835
                          
                          
                          
                          90,245Amounts due to
      related parties
                          
                          
                          2,824,070
                          
                          
                          
                          1,524,321Current portion of
      long-term debts
                          
                          
                          6,760
                          
                          
                          
                          8,2374,361,665
                          
                          
                          
                          2,976,585Long-Term
      Debts
                          
                          
                          450
                          
                          
                          
                          6,860Total
      Liabilities
                          
                          
                          4,362,115
                          
                          
                          
                          2,983,445Stockholders'
      Equity (Deficit)Preferred stock,
      $.0001 par value; 3,000,000 shares authorized;None issued and
      outstanding as of December 31, 2007Common stock,
      $.0001 par value; 100,000,000 shares authorized;57,344,375 and
      27,058,663 shares issued andOutstanding,
      respectively
                          
                          
                          5,734
                          
                          
                          
                          2,706Additional paid-in
      capital
                          
                          
                          7,453,883
                          
                          
                          
                          6,804,339Deficit
                          
                          
                          (11,007,866
                          )
                          
                          
                          (9,333,413
                          )Other comprehensive
      income (loss)
                          
                          
                          (33,506
                          )
                          
                          
                          (103,087)Total Stockholders' Equity
      (Deficit)
                          
                          
                          (3,581,755
                          )
                          
                          
                          (2,629,455
                          )Total Liabilities
      and Stockholders' Equity (Deficit)
                          
                          $
                          780,360
                          
                          
                          $
                          353,990






4











Medical
      International Technology, Inc.
            Quarterly Financial
      Report







CONSOLIDATED STATEMENTS OF
OPERATIONS







Three-Months
      Period Ended
                                June
      30,
                              
                              
                              Nine-Months
      Period Ended
                                June
      30,2009
                                (Unaudited)
                              
                              
                              2008
                                (Unaudited)
                              
                              
                              2009
                                (Unaudited)
                              
                              
                              2008
                                (Unaudited)Sales
                              
                              $
                              234,060
                              
                              
                              $
                              140,553
                              
                              
                              $
                              392,977
                              
                              
                              $
                              306,060Cost
      of sales
                              
                              
                              ( 62,820
                              )
                              
                              
                              37,655
                              
                              
                              
                              (148,581
                              )
                              
                              
                              136,986Gross
      profit (loss)
                              
                              
                              171,240
                              
                              
                              
                              102,898
                              
                              
                              
                              244,396
                              
                              
                              
                              169,074Research
      and development costs
                              
                              
                              (581,373
                              )
                              
                              
                              (78,990
                              )
                              
                              
                              (1,481,373
                              )
                              
                              
                              102,063Selling,
      general, and administrative expenses
                              
                              
                              (171,085
                              )
                              
                              
                              427,268
                              
                              
                              
                              (437,323
                              )
                              
                              
                              763,372(752,458
                              )
                              
                              
                              348,278
                              
                              
                              
                              (1,918,696
                              )
                              
                              
                              865,435Loss
      from operations
                              
                              
                              (581,218
                              )
                              
                              
                              (245,380
                              )
                              
                              
                              (1,674,300
                              )
                              
                              
                              (696,361
                              )Other
      Income (Expense)Interest
      income/loss
                              
                              
                              1,361
                              
                              
                              
                              152
                              
                              
                              
                              1,875
                              
                              
                              
                              12,419Interest
      expense
                              
                              
                              (848
                              )
                              
                              
                              (975
                              )
                              
                              
                              (2,027
                              )
                              
                              
                              (17,092
                              )513
                              
                              
                              
                              ( 823
                              )
                              
                              
                              (152
                              )
                              
                              
                              (4,673
                              )Net
      Loss
                              
                              $
                              (580,705
                              )
                              
                              $
                              (246,203
                              )
                              
                              $
                              (1,674,452
                              )
                              
                              $
                              (701,034
                              )Basic
      (loss) per share
                              
                              $
                              (0.01
                              )
                              
                              $
                              (0.009
                              )
                              
                              $
                              (0.029
                              )
                              
                              $
                              (0.02
                              )Basic
      weighted average shares outstanding
                              
                              
                              57,344,375
                              
                              
                              
                              27,058,663
                              
                              
                              
                              57,344,375
                              
                              
                              
                              27,058,663






5







Medical
      International Technology, Inc.
            Quarterly Financial
      Report




CONSOLIDATED STATEMENTS OF CASH
      FLOWSNine-Month
      Period EndedJune
      30,2009
                              
                              
                              2008Cash
      Flows from Operating Activities
                              
                              (Unaudited)
                              
                              
                              (Unaudited)Net
      Loss
                              
                              $
                              (1,674,452
                              )
                              
                              $
                              (701,034
                              )Adjustments to
      reconcile net loss to net cashUsed in
      operating activities:Depreciation
      and amortization expense
                              
                              
                              38,407
                              
                              
                              
                              41,468Common
      stock issued for consulting and legal services
                              
                              
                              2,400
                              
                              
                              
                              -Common
      stock issued for additional capital
                              
                              
                              628
                              
                              
                              
                              -(Increase)
      decrease in Assets(Increase)
      decrease in accounts receivable
                              
                              
                              (31,251
                              )
                              
                              
                              6,937(Increase)
      decrease in inventories
                              
                              
                              (22,159
                              )
                              
                              
                              5,926(Increase)
      decrease in research tax credit receivable
                              
                              
                              -
                              
                              
                              
                              23,742(Increase)
      decrease in prepaid expenses
                              
                              
                              8
                              
                              
                              
                              (32)Increase
      (decrease) in LiabilitiesIncrease
      (decrease) in deferred income
                              
                              
                              (118,782)
                              
                              
                              
                              1,358,752Increase
      (decrease) in accounts payable and accrued expenses
                              
                              
                              205,590
                              
                              
                              
                              (118,626
                              )Net
      Cash Used in Operating Activities
                              
                              
                              (1,599,611
                              )
                              
                              
                              617,133Cash
      Flows from Investing ActivitiesEquipment
      acquisition
                              
                              
                              -
                              
                              
                              
                              (3,423
                              )Net
      cash used in investing activities
                              
                              
                              -
                              
                              
                              
                              (3,423
                              )Cash
      Flows from Financing ActivitiesInvestment
                              
                              
                              (406,100)
                              
                              
                              
                              
                              -Gross
      proceeds from private offering
                              
                              
                              649,543
                              
                              
                              
                              -Common
      stock issued for debt reductions
                              
                              
                              -
                              
                              
                              
                              
                              -Increases
      (reductions) in amounts due to related parties
                              
                              
                              1,299,749
                              
                              
                              
                              (49,696
                              )Principal
      reduction on small business loan
                              
                              
                              (7,887
                              )
                              
                              
                              (267,356
                              )Net
      Cash Provided by Financing Activities
                              
                              
                              1,535,305
                              
                              
                              
                              (326,052
                              )Effect
      of exchange rates on cash
                              
                              
                              69,581
                              
                              
                              
                              (276,151
                              )Net
      Increase (decrease) in Cash and Cash Equivalents
                              
                              
                              5,275
                              
                              
                              
                              11,507Beginning
      Balance - Cash and Cash Equivalents
                              
                              
                              94,834
                              
                              
                              
                              187,536Ending
      Balance - Cash and Cash Equivalents
                              
                              $
                              100,109
                              
                              
                              $
                              199,043Supplemental
      Information:Cash Paid
      For:Interest
      Expenses
                              
                              $
                              2,027
                              
                              
                              
                              17,092Income
      Taxes
                              
                              $
                              -
                              
                              
                              $
                              -$
                              
                              
                              
                              $
                              -






6
   Medical
      International Technology, Inc.
              Quarterly Financial
      Report






CONSOLIDATED STATEMENTS OF COMPREHENSIVE
      LOSSThird
      quarter ending
                          June
      30,
                          2009
                        
                        
                        Third
                          quarter
      ending
                          June
      30,
                          2008Net
      loss
                        
                        $
                        (1,674,452
                        )
                        
                        $
                        (701,034
                        )Other
      comprehensive income (loss)Foreign
      currency translation adjustment
                        
                        
                        69,581
                        
                        
                        
                        (276,151)Net comprehensive income (loss)
                        
                        $
                        (1,604,871
                        )
                        
                        $
                        (977,185
                        )











7






Medical
      International Technology, Inc.
            Quarterly Financial
      Report




Notes
to Financial Statements





(Unaudited)







Note
1 – Basis of Presentation




Interim
Financial Statements


The
accompanying unaudited condensed consolidated financial statements of Medical
International Technology, Inc. and its subsidiary (collectively referred to as
the “Company”) have been prepared in accordance with accounting principles
generally accepted in the United States of America, pursuant to the rules and
regulations of the Securities and Exchange Commission.  All
significant intercompany balances and transactions have been
eliminated.  These financial statements do not include all information
and notes required by accounting principles generally accepted in the United
States of America for complete financial statements.  It is
recommended that these interim unaudited condensed consolidated financial
statements be read in conjunction with the consolidated financial statements and
notes thereto included in the Company's Annual Report on Form 10-K for the
fiscal year ended September 30, 2009.




In the
opinion of management, all adjustments (consisting only of normal recurring
accruals) considered necessary for a fair presentation have been
included.  Operating results for the nine month period ended June 30,
2009 are not necessarily indicative of the results which may be expected for any
other interim periods or for the year ending September 30, 2010. The preparation
of financial statements in conformity with accounting principles generally
accepted in the United States of America requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from these estimates.




Note
2 – Unearned income





On
November 1st, 2007, the Company received a Non-Refundable deposit of $1,300,000
for the worldwide rights to market and sells all Medical International
Technology Inc.’s present and future Needle-Free Jet-Injectors for the human and
animal markets. This deposit is part of an agreement under negotiation, and
will be disclosed when finalized, which the Company expects to occur in fiscal
2009.  The Company has recorded the deposit as unearned income until
such time as a final agreement is reached, at which time the deposit will be
earned as income over the estimated contractual life of the final
agreement.As at June
30, 2009, the Company had earned$ 65,000.


Note
3 – Inventories




Inventories
at June 30, 2009 and September 30, 2008 consist of the
following:




June
      30,
                    2009
                  
                  
                  September
      30,
                    2008Raw
      materials
                  
                  $
                  144,012
                  
                  
                  $
                  139,604Work
      in process
                  
                  
                  42,762
                  
                  
                  
                  23,863Finished
      goods
                  
                  
                  4,844
                  
                  
                  
                  5,992Total
                  
                  $
                  191,618
                  
                  
                  $
                  169,459






8






Medical
      International Technology, Inc.
            Quarterly Financial
      Report




Notes
to Financial Statements





(Unaudited)






Note
4 – Research Credit Receivable




Research
and development costs are charged to operations when incurred. For its research
efforts in Canada, the Company receives a cash payment from the Canadian
Government based upon the amount actually incurred. The Company nets the credit
against related costs charged to operations. Research and development expenses
are as follows:




June
      30,
                    2009
                  
                  
                  September
      30,
                    2008R&D
      Costs
                  
                  $
                  1,481,373
                  
                  
                  $
                  1,802,857Less
      Credit
                  
                  
                  -
                  
                  
                  
                  (3,158
                  )$
                  1,481,373
                  
                  
                  $
                  1,802,085




Note
5 – Property and Equipment




The cost
of property and equipment is depreciated over the estimated useful lives of the
related assets, which range from 5 to 7 years. Depreciation is computed on the
straight-line method for financial reporting purposes and on the declining
balance method for income tax reporting purposes. Depreciation expense for the
nine-months ended June 30, 2009 and 2008 was $38,058 and $41,119
respectively.




Note
6 – Intangible Assets




As of
June 30, 2009 the Company has net intangible assets totaling $ 283. Amortization
expenses for the nine-months ended June 30, 2009 and 2008 were $349 and $349,
respectively.  Intangible assets consist of the
following:




Gross
                    Intangible
                    Assets
                  
                  
                  Accumulated
      Amortization
                  
                  
                  Net
                    Intangible
                    Assets
                  
                  Weighted
                    Average
                    Life
                    (Years)Patents
                  
                  $
                  2,030
                  
                  
                  $
                  1,747
                  
                  
                  $
                  283
                  
                  8.5
      through 16




Note
7 – Related Party Transactions




Related
party balances consist of the following at Jun30, 2009 and September 30,
2008:




June
      30,
                    2009
                  
                  
                  September
      30,
                    2008Payable
      to Idée International R&D, Inc.
                  
                  $
                  2,824,070
                  
                  
                  $
                  1,480,378Payable
      to 2849-674 Canada, Inc.
                  
                  
                  -
                  
                  
                  
                  34,637Payable
      to 9117-2221 Quebec Inc.
                  
                  
                  -
                  
                  
                  
                  9,306$
                  2,824,070
                  
                  
                  $
                  1,524,321







9








Medical
      International Technology, Inc.
            Quarterly Financial
      Report




Notes
to Financial Statements





(Unaudited)


Note 8 – Common
Stock





Common
Stock


From time
to time, the Company will issue common stock for services rendered, debt
reductions or as part of private placement offerings.  For the quarter
ended March 31, 2009, the Company issued 20,000,000 shares of common stock to a
related party for payment of outstanding payables of $20,000.  In
addition, the Company issued 2,000,000 shares of common stock to the Company’s
Chief Executive Officer and 2,000,000 shares to the Company’s Chief Financial
Officer for services rendered to the Company.  The value of those
services was $4,000.





For the
quarter ended June 30, 2009, the Company issued 6,285,712 shares of common stock
for additional capital of $628,571.




Preferred
Stock




As of
June 30, 2009, there was no preferred stock outstanding. Dividend features and
voting rights are at the discretion of the Board of Directors without the
requirement of shareholder approval.




Outstanding
Options




As of
June 30, 2009, there were no outstanding stock options.




Outstanding
Warrants




As of
June 30, 2009, there were no outstanding warrants.




Note
9 – Notes Payable





Long-term
debt consists of the following at June 30, 2009 and September 30,
2008:




June
      30,
                      2009
                    
                    
                    September
      30,
                      2008Note
      payable to a bank, bearing interest at prime plus
    2.5%Secured by equipment, due July 21, 2010.
                    
                    $
                    7,211
                    
                    
                    $
                    15,097Current
      portion of long-term debt
                    
                    
                    6,760
                    
                    
                    
                    (8,237
                    )Long-term
      debt
                    
                    $
                    450
                    
                    
                    $
                    6,860Scheduled
      maturities of long-term debt are as follows:June
      30, 2010
                    
                    
                    6,760July
      21, 2010
                    
                    
                    450








10







Medical
      International Technology, Inc.
            Quarterly Financial
      Report




Notes
to Financial Statements





(Unaudited)


Note
10 – Investment in Joint Venture
 
 On May 6,
2009, the Company entered into a certain joint venture agreement (the “Joint
Venture Agreement”) with Jiangsu Hualan Biotechnology Ltd. (China) (“Jiangsu
Hualan”).   Pursuant to the Joint Venture Agreement, the parties
established a joint venture company, Jiangsu Hualan MIT Medical Technology (MIT
China) Ltd. (“MIT China” or the “Joint Venture”), focusing on research,
production and sales of medical equipments, import and export of medical
equipments and components products, especially Needle-Free Jet Injector
products. The total investment by the Joint Venture shall amount to $2,000,000,
and the registered capital shall amount to $1,400,000.  The Company
invested cash of $406,100 and transferred the license rights to produce and sell
the Company’s needle-free injectors products into the Joint
Venture.  The license rights were valued at $280,000 under the
agreement.  The contributions by the Company resulted in the Company
owning 49% of the registered capital of the Joint Venture.  Jiangsu
Hualan contributed cash of $714,000, and owns 51% of the registered
capital.
 
 Under the
agreement, the Company appointed 1 member to the Board of Directors of the Joint
Venture and Jiangsu Hualan appointed  2 members to the Board of
Directors.  Profits of the Joint Venture will be paid based each
parties investment in the registered capital.
 
 During
the period from May 6, 2009 to June 30, 2009, the Joint Venture had not
commenced operations .  The Company expects the Joint Venture to
commence operations during the Company’s fourth quarter of fiscal
2009.
 
 As of
June 30, 2009, the Company recorded an investment in the Joint Venture of
$406,100, representing the cash contributed to the Joint Venture.  The
Company has determined the recorded investment approximates the Company’s value
in the equity of the Joint Venture at June 30. 2009.


Note
11 – Contingencies




Legal
Proceedings




From time
to time, the Company is named in legal actions in the normal course of business.
In the opinion of management, the outcome of these matters, if any, will not
have a material impact on the financial condition or results of operations of
the Company.









11




Medical
International Technology, Inc.








Item
2.   Management's Discussion and Analysis of Financial Condition
and Plan of Operations




This
quarterly report on Form 10-Q and other reports filed by Registrant from time to
time with the Securities and Exchange Commission (collectively the “Filings”)
contain or may contain forward-looking statements and information that are based
upon beliefs of, and information currently available to, Registrant’s management
as well as estimates and assumptions made by Registrant’s management. Readers
are cautioned not to place undue reliance on these forward-looking statements,
which are only predictions and speak only as of the date hereof. When used in
the filings, the words “anticipate”, “believe”, “estimate”, “expect”, “future”,
“intend”, “plan”, or the negative of these terms and similar expressions as they
relate to Registrant or Registrant’s management identify forward-looking
statements. Such statements reflect the current view of Registrant with respect
to future events and are subject to risks, uncertainties, assumptions, and other
factors (including the risks contained in the section of this report entitled
“Risk Factors”) relating to Registrant’s industry, Registrant’s operations and
results of operations, and any businesses that Registrant may acquire. Should
one or more of these risks or uncertainties materialize, or should the
underlying assumptions prove incorrect, actual results may differ significantly
from those anticipated, believed, estimated, expected, intended, or
planned.




Although
Registrant believes that the expectations reflected in the forward-looking
statements are reasonable, Registrant cannot guarantee future results, levels of
activity, performance, or achievements. Except as required by applicable law,
including the securities laws of the United States, the Registrant does not
intend to update any of the forward-looking statements to conform these
statements to actual results. Readers are urged to carefully review and consider
the various disclosures made throughout the entirety of this quarterly report,
which attempt to advise interested parties of the risks and factors that may
affect our business, financial condition, results of operations, and
prospects.




Financial
Summary




Results of Operations for
the Nine-Months ended June 30, 2009 and 2008




For the
nine-month period ended June 30, 2009, the Company experienced a net loss from
operations of  $1,674,300 which was primarily due to research and
development costs of  $1,481,373 and selling, general and
administrative expenses of  $437,323. Gross profits for the period
were $244,396.





For the
nine-month period ended June 30, 2008, the Company’s net loss from operations
was $696,361, which was primarily due to research and development costs
of  $102,063 and selling, general and administrative expenses of
$763,372. Gross profits for this period were $169,074.





For the
nine-months ended June 30, 2009, the Company experienced an increase in sales
compared to sales for the same period last year. Sales for the nine-month period
ending June 30, 2009 were $392,977 compared to sales of $306,060 for the same
period last year. Gross profits for the none-month period ending June 30, 2009
represented 62% of sales, where gross profits for the same period last year
represented 55% of sales.




Results of Operations for
the Three-Months ended June 30, 2009 and 2008




For the
three-month period ended June 30, 2009, the Company experienced a net loss from
operations of  $581,218 which was primarily due to research and
development costs of  $581,373 and selling, general and administrative
expenses of  $171,085. Gross profits for the period were
$171,240.





For the
three-month period ended June 30, 2008, the Company’s net loss from operations
was $245,380, which was primarily due to research and development costs
of  $78,990 and selling, general and administrative expenses of
$427,268. Gross profits for this period were $02,898.





For the
three-months ended June 30, 2009, the Company experienced an increase in sales
compared to sales for the same period last year. Sales for the three-month
period ending June 30, 2009 were $234,060 compared to sales of $140,553 for the
same period last year. Gross profits for the three-month period ending June 30,
2009 represented 73% of sales, where gross profits for the same period last year
represented 73% of sales.





Liquidity and Capital
Resources





For the
nine-month period ending June 30, 2009, the Company’s cash position increased
$5,275. Net cash used in operating activities was $950,068; financing activities
provided $885,762; and the effect of exchange rates on cash provided
$69,581.




For the
nine-month period ending June 30, 2008, the Company’s cash position increased
$11,507. Net cash used in operating activities was $617,133; financing
activities provided $326,052; and the effect of exchange rates on cash provided
$276,151.







12






Management
Plan of Operations





Medical
International Technology, Inc. (“MIT”) is engaged in the business of research,
development, marketing and sales of needle-free jet injector technology and
products for humans and animals, for single and mass injections.





We
continue to market our product in all available markets, seek regulatory
approvals to expand those market opportunities and improve our products for
application to new markets.




On May 6,
2009, the Company entered into a certain joint venture agreement (the “Joint
Venture Agreement”) with Jiangsu Hualan Biotechnology Ltd. (China) (“Jiangsu
Hualan”).   Pursuant to the Joint Venture Agreement, the parties
established a joint venture company, Jiangsu Hualan MIT Medical Technology (MIT
China) Ltd. (“MIT China” or the “Joint Venture”), focusing on research,
production and sales of medical equipments, import and export of medical
equipments and components products, especially Needle-Free Jet Injector
products.





Medical
International Technology, Inc. will continue to seek additional funding to
expand operations and develop sales revenue to a volume sufficient to sustain
operations.




Product
Development





Medical
International Technologies is still working towards getting FDA approval for its
needle-free injector, few more test are required and are being planned – the
MED-JET, designed specifically for human mass inoculations. The MED-JET is
capable of delivering many types of medications such as vaccines, insulin and
other types of injectables. Its low-pressure technology offers an advantage to
alternative high pressure systems that can cause blowbacks and expose medical
workers and patients alike to microscopic traces of blood.





According
to the International Sharps Injury Prevention Society (http://www.isips.org), it
has been estimated that one out


of every
seven workers is accidentally stuck by a contaminated sharp point each and every
year. The Center for Disease Control (CDC:
http://www.cdc.gov/niosh/2000-108.html#5) estimates that there are 600,000 to
800,000 needle stick injuries per year in the U.S. alone, and many are not
reported. More than 20 types of infectious agents have been transmitted through
needlesticks, including hepatitis B and C, tuberculosis, syphilis, malaria,
herpes, diphtheria, gonorrhea, typhus and Rocky Mountain spotted fever. The
MED-JET will eliminate this risk to our health care professionals and create a
safer workplace.





Other
advantages include its light weight (0.5 kg) and an excellent medication
absorption rate. Additionally, the system has the ability to increase or
decrease the volume and pressure of injection. This technology is unique to
MIT’s MED-JET MBX Injector. The system is designed to inject up to 600
individuals an hour.





The
approval process can be expensive and may take extended period of time. There
can be no assurance that this system will receive approval from the FDA or if
approved gain broad acceptance by the medical community or individual
patients.





On
December 15, 2005, Medical International Technologies, Inc announced that it has
received full certification granted under the International Organization for
Standardization, as well as the Canadian Medical Device Conformity Assessment
System, for devices to be licensed by HEALTH CANADA. These certifications allow
MIT to market the Med-Jet Needle-Free Injector for human use in all countries
other than the U.S., MIT is working towards getting FDA approval, more test are
required and are being planned at this point. The Med-Jet injector will be
submitted for FDA approval as soon as we complete the required testing which, if
accepted, will allow MIT to sell the Med-Jet in the United States, making it a
truly worldwide system.





MIT's
Needle-Free Injection System, designed specifically to allow fast, accurate and
safe injections, is rapidly moving toward establishing itself as a valuable
instrument in the fight against disease in both humans and animals. Spurred on
by growing fears of a world wide pandemic that could match or even exceed the
deadly flu pandemic of 1918, which killed millions of people, the MIT team is
focusing its efforts to make its Needle-Free Injection System available to the
world.





Now that
MIT is able to sell its Med-Jet in all countries, other than the U.S., it is
working to complete the FDA filings. The first of these will be for use of the
Med-Jet for injecting anesthesia in a variety of situations. The second, and
most significant in light of the news coming out of Mexico and USA and other
countries around the world concerning the spread of Influenza A (H1N1) to
humans, will be the Med-Jet-H-III, for mass vaccination in case of a pandemic,
such as Avian Influenza, Polio, Tuberculosis, Malaria or HIV.





MIT is
also pursuing increasing interest in its Agro-Jet needle-free injector. Having
the same benefits as Med-Jet, Agro-Jet will become a valuable instrument in the
fight against many diseases such as Swine Flue and Avian Flu via its ability to
mass inoculate animals at over 1000 injections per hour.





Item
3.   Quantitative and Qualitative Disclosures About Market
Risk





Not
required for Smaller Reporting Companies.







13






Item
4.   Controls and Procedures





Evaluation of Disclosure
Controls and Procedures





Pursuant
to Rule 13a-15(b) under the Securities Exchange Act of 1934 (“Exchange Act”),
the Company carried out an evaluation, with the participation of the Company’s
management, including the Company’s Chief Executive Officer (“CEO”) and Chief
Financial Officer (“CFO”),of the effectiveness of the Company’s disclosure
controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act)
as of the end of the period covered by this report. Based upon that evaluation,
the Company’s CEO and CFO concluded that the Company’s disclosure controls and
procedures are effective to ensure that information required to be disclosed by
the Company in the reports that the Company files or submits under the Exchange
Act, is recorded, processed, summarized and reported, within the time periods
specified in the SEC’s rules and forms, and that such information is accumulated
and communicated to the Company’s management, including the Company’s CEO and
CFO, as appropriate, to allow timely decisions regarding required
disclosure.





Changes in Internal
Controls





There
have been no changes in the Company’s internal control over financial reporting
during the quarter ended June 30, 2009 that have materially affected, or are
reasonably likely to materially affect, the Company's internal control over
financial reporting.




PART
II OTHER INFORMATION





Item
1.   Legal Proceedings




We are
currently not involved in any litigation that we believe could have a material
adverse effect on our financial condition or results of operations. There is no
action, suit, proceeding, inquiry or investigation before or by any court,
public board, government agency, self-regulatory organization or body pending
or, to the knowledge of the executive officers of our company or any of our
subsidiaries, threatened against or affecting our company, our common stock, any
of our subsidiaries or of our companies or our subsidiaries’ officers or
directors in their capacities as such, in which an adverse decision could have a
material adverse effect.




Item
1A. Risk Factors





Not
required for Smaller Reporting Companies.





Item
2.   Unregistered Sales of Equity Securities and Use of
Proceeds





None.





Item
3.   Defaults upon Senior Securities





None





Item
4.   Submission of Matters to a Vote of Security Holders





None





Item
5.   Other information




None





Item
6.   Exhibits




31.1         Certification
of Principal Executive Officer and Principal Accounting Officer pursuant to Rule
13a-14(a)/15(d)-14(a)).




32.1         Certification
of Principal Executive Officer and Principal Accounting Officer pursuant to
(18U.S.C. 1350)









14








SIGNATURES





In
accordance with the requirements of the Exchange Act, the registrant caused this
report to be signed on its behalf by the undersigned, thereunto duly
authorized.






Medical International
      Technology, Inc.Date:
      August 14, 2009
              By:
              /s/ Karim
      MenassaKarim
      MenassaPresident
      and Principal Executive Officer
                And
      interim Secretary and Principal Accounting Officer








16